Cardiol Therapeutics (CRDL) Shares Outstanding (Diluted Average) (2020 - 2025)

Cardiol Therapeutics has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $62.4 million in Q4 2025.

• For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 21.76% year-over-year to $62.4 million; the trailing twelve-month figure through Dec 2025 stood at $62.4 million (up 21.76% YoY), and the FY2025 full-year result was $62.4 million, up 21.76% from the prior year.
• Shares Outstanding (Diluted Average) for Q4 2025 stood at $62.4 million, up from $51.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $62.4 million in Q4 2025, with the low at $34.3 million in Q4 2021.
• Historically, Shares Outstanding (Diluted Average) has averaged $48.3 million across 5 years, with a median of $47.4 million in 2023.
• Annual changes were most pronounced in 2021 — Shares Outstanding (Diluted Average) soared 49.73% — and 2023, when it advanced 2.83%.
• Cardiol Therapeutics' Shares Outstanding (Diluted Average) stood at $34.3 million in 2021, then jumped by 34.29% to $46.0 million in 2022, then climbed by 2.83% to $47.4 million in 2023, then gained by 8.2% to $51.2 million in 2024, then gained by 21.76% to $62.4 million in 2025.
• The last three Shares Outstanding (Diluted Average) figures came in at $62.4 million (Q4 2025), $51.2 million (Q4 2024), and $47.4 million (Q4 2023), per Business Quant data.